Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
0.7126 ^USD	-1.78%		+0.23%	-91.05%

05-08	Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	US Equity Markets Close Mixed After March Producer Price Inflation Data	MT

Aptevo Therapeutics Inc. Announces Resignation of Jane Gross as Chief Scientific Officer, Effective September 14, 2021

August 27, 2021 at 02:01 pm

On August 25, 2021, Jane Gross resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. effective September 14, 2021 and agreed to transition into a consulting relationship with the company through December 31, 2021, as described in an Executive Transition Services Agreement signed by Gross and the company.

Latest news about Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
US Equity Markets Close Mixed After March Producer Price Inflation Data	04-11	MT
Top Midday Decliners	04-11	MT
Top Premarket Decliners	04-11	MT
Aptevo Therapeutics Inc. Provides Pipeline Update	04-10	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	03-07	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Certain Warrants of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 3-NOV-2023.	11-02	CI
Certain Stock Options of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 3-NOV-2023.	11-02	CI
Certain Common Stock of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 3-NOV-2023.	11-02	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Aptevo Therapeutics Prices Offering of 8 Million Shares, Expects $5 Million Gross Proceeds	02/08/23	MT
Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML	18/07/23	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
XOMA Acquires Commercial Payment, Portion of Milestone Rights to Ixinity For $9.6 Million	30/03/23	MT
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Aptevo Therapeutics Inc. Appoints Jeffrey G. Lamothe to Executive Vice President, Chief Operating Officer	07/03/23	CI
Aptevo Therapeutics Inc. Announces Chief Financial Officer Changes	07/03/23	CI
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial	13/02/23	CI
Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors	09/01/23	CI
Sector Update: Health Care Stocks Carried Higher with Broader Markets	12/12/22	MT
Sector Update: Health Care	12/12/22	MT
Top Midday Gainers	12/12/22	MT
Aptevo Therapeutics Says Leukemia Combination Therapy Showed Clinical Benefit in Early Stage Study	12/12/22	MT

Chart Aptevo Therapeutics Inc.

Duration

Period

More charts

Company Profile

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Sector

Biotechnology & Medical Research

Calendar

07/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7126 USD

Average target price

605 USD

Spread / Average Target

+84,800.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APTEVO THERAPEUTICS INC.	-91.05%	1.15M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs